For a peptide promoted to athletes, wellness clinics and online buyers for years, BPC-157 has a remarkably thin record in humans.
That gap became more important on October 28, 2026, when the U.S. Department of Health and Human Services announced that it would exercise limited enforcement discretion for pharmacies and physicians compounding BPC-157 under specified conditions.
The announcement, published in the Federal Register on October 30, changed the federal enforcement approach without making BPC-157 an FDA-approved drug or establishing that it works.
Meanwhile, a registered Phase 2 trial in Shenzhen, China, is designed to test BPC-157 against placebo in 120 adults with acute hamstring injuries. Its estimated primary completion date is February 2027, but its overall study completion is not expected until February 2028. No efficacy results have been posted.
Those two developments point to the central contradiction in the current BPC-157 debate. Federal officials are allowing a narrow route for compounded products before randomized human evidence has established whether the peptide provides meaningful clinical benefit.
The question is not simply whether BPC-157 is available. It is what the science actually supports, what the October policy permits and what the first registered placebo-controlled hamstring trial can eventually tell us.
The BPC-157 FDA Status After the October Policy
BPC-157, also called Body Protective Compound-157, is a synthetic peptide containing 15 amino acids. It is described in the scientific literature as derived from a sequence associated with gastric proteins.
It has attracted interest because animal and laboratory studies suggest effects on tissue repair, inflammation, blood-vessel formation and several biochemical pathways associated with healing.
None of those proposed benefits has yet been established through adequate controlled human trials.
BPC-157 has never received FDA approval for treating injury, pain, gastrointestinal disease or any other condition.
For several years, its regulatory position in the United States has been complicated by the distinction between approved medicines, pharmacy-compounded preparations and products sold online for purported research use.
The FDA previously included BPC-157 among nominated bulk drug substances in Category 2, a category covering substances the agency had identified as potentially presenting significant safety risks when used in compounding.
On April 22, 2026, BPC-157 and five other peptides were removed from that category. As Holland & Knight explained in its November 4 legal analysis, removal did not automatically make the peptides eligible for ordinary compounding under Section 503A of the Federal Food, Drug, and Cosmetic Act.
Under that framework, bulk substances generally must meet specific eligibility requirements, such as an applicable USP or National Formulary monograph, inclusion in an FDA-approved drug or placement on the FDA’s formal 503A Bulks List.
The six peptides addressed in the October policy had not been added to that formal list.
Instead, the HHS Office of the Secretary announced an interim enforcement discretion policy. The notice was filed October 28 and formally published in the Federal Register on October 30, 2026.
The policy covers BPC-157, epitalon, KPV, MOTS-c, Semax and TB-500. It states that HHS does not intend to take enforcement action against specified Section 503A compounders using those ingredients when all ten policy conditions are satisfied.
For BPC-157, the policy specifies the acetate form and identifies subcutaneous, intramuscular, oral and topical dosage forms within its limited scope.
Among the requirements are patient-specific prescriptions, appropriate ingredient identification, validated certificates of analysis, sourcing from registered manufacturers, restrictions on combining active ingredients, specific labeling and adverse-event reporting.
The original manufacturer must satisfy relevant registration and manufacturing requirements, while the compounder must also comply with applicable federal and state laws.
These safeguards concern how a product may be prepared and distributed within the temporary enforcement framework. They do not demonstrate that BPC-157 is effective or safe for a particular disease.
The policy was issued by HHS rather than through the usual FDA drug-approval process. It followed a Pharmacy Compounding Advisory Committee recommendation supporting inclusion of several peptides on the 503A list, despite FDA scientific reviewers recommending against that step.
HHS has also stated that the interim policy may be reconsidered if safety or product-quality problems arise. It creates no enforceable rights and does not override state restrictions.
The Federal Register notice invited public comments through the two-week period following October 30, with November 13 as the published deadline.
The practical outcome is narrow: some licensed compounders may fall within the federal policy’s conditional enforcement discretion. BPC-157 itself remains an unapproved drug substance.
Grey Pepper has examined the policy’s details in Six Peptides, Ten Conditions: Washington Opens a Narrow Compounding Door.
Washington changed its approach to enforcement. It did not establish that BPC-157 works, or that compounded BPC-157 has passed FDA review.
What the BPC-157 Human Studies Actually Show
The scientific literature on BPC-157 looks substantially larger when animal studies are counted than when the focus turns to people.
Preclinical researchers have investigated effects involving angiogenesis, collagen production, fibroblast activity, nitric oxide signaling and inflammatory pathways across models of muscle, tendon, ligament, bone and gastrointestinal injury.
These experiments provide hypotheses about possible biological activity. They do not establish that the peptide improves recovery, reduces pain or is safe for human use.
A March 2026 review in the International Journal of Molecular Sciences, led by Claire Yuan, summarized the preclinical evidence and emphasized the shortage of rigorous human research.
An even more focused assessment appeared on October 8, 2026, in Acta Orthopaedica Belgica. Researchers J. T. Poolton, J. Minett and A. Kazmi systematically reviewed the human evidence, searching Embase, PubMed, the Cochrane Library and ClinicalTrials.gov through June 1.
They identified just three published human studies involving 30 participants in total.
The studies comprised a retrospective knee-pain investigation involving 16 patients, a retrospective pilot study involving 12 women with interstitial cystitis and a short intravenous safety pilot involving two adults.
None was a randomized, placebo-controlled trial. All were judged methodologically weak, and the certainty of the clinical evidence was rated very low.
The knee-pain study, published in 2021 by Edwin Lee and Blake Padgett, reviewed outcomes among patients who had received injections containing BPC-157 alone or in combination with thymosin beta-4.
Of 16 patients contacted during follow-up, 14 reported some relief of knee pain.
That sounds encouraging, but it cannot establish that BPC-157 caused the improvement. There was no untreated comparison group, no randomized allocation, no blinding and no standardized controlled assessment demonstrating tissue repair.
Some participants received two experimental peptides rather than BPC-157 alone, making attribution even more difficult.
The interstitial-cystitis pilot, published in 2024, described 12 women who received BPC-157 administered around areas of bladder inflammation during a cystoscopic procedure.
All 12 reported symptom improvement, with ten describing complete symptom resolution. However, the study lacked a control group, depended substantially on patient-reported outcomes and could not distinguish treatment effect from other explanations.
The third study was a 2025 intravenous safety pilot by Edwin Lee and Kailynd Burgess. It followed two adults who had previously received intravenous BPC-157.
Neither participant reported an adverse event during the short observation period, and the investigators did not identify concerning changes in the monitored laboratory measurements involving cardiac, hepatic, renal, thyroid or glucose-related parameters.
But two selected participants, short exposure and follow-up extending only several days cannot establish a broad safety profile.
Such a study cannot reliably detect uncommon adverse reactions, problems that emerge after repeated exposure, immunogenicity or long-term consequences.
The October systematic review concluded that the published evidence was insufficient to support clinical use outside regulated, ethically approved, high-quality clinical trials.
That conclusion is substantially more informative than counting positive anecdotes.
Thirty participants across three uncontrolled studies are not an established treatment record, even when most reported favorable outcomes.
Inside the First Registered Placebo-Controlled Hamstring Trial
The most important new clinical development is a registered Phase 2 trial identified as NCT07437547.
According to its ClinicalTrials.gov registration, the study is sponsored by Hudson Biotech and is designed to investigate BPC-157 for acute grade II hamstring muscle strains confirmed by magnetic resonance imaging.
The study lists Peking University Shenzhen Hospital in Shenzhen, China, as its research site and targets enrollment of 120 adults aged 18 to 45.
The registered design is randomized, placebo-controlled and masked, with participants assigned in a 1:1 ratio to active treatment or matching placebo.
Both groups receive a standardized rehabilitation program supervised by study physiotherapists. That is important because rehabilitation is an established component of hamstring injury management, and investigators need to determine whether adding BPC-157 produces benefits beyond the shared rehabilitation intervention.
The registered treatment period is 14 days, with follow-up assessments scheduled over subsequent weeks.
The study has two primary outcome measures.
The first is time to unrestricted return to sport, assessed over eight weeks using clinical clearance and a standardized functional performance battery.
The second is the change in MRI-measured hamstring injury volume from baseline to day 14, assessed through blinded radiological review.
These endpoints examine different aspects of recovery. Return to sport is a practical functional measure, while MRI injury volume provides an imaging-based assessment of structural change.
The trial also lists secondary outcomes involving pain during activity, hamstring strength and lower-extremity function.
This design is substantially stronger than the uncontrolled reports that currently dominate BPC-157’s human literature.
Randomization can help balance differences between treatment groups. A matching placebo can reduce expectation-related bias. Blinded outcome assessment can strengthen interpretation of both imaging and functional measurements.
But the registry is not perfectly clear.
The published arm listings appear to associate both the experimental drug and placebo with both groups, and the placebo arm is also classified as experimental. The detailed description specifies the intended comparison more clearly, but those inconsistencies should be corrected or clarified by the sponsor.
The trial record lists February 2, 2026, as its start date and February 27 as its first public posting date.
Its estimated primary completion date is February 14, 2027. However, estimated overall study completion is February 17, 2028.
Those dates represent planned milestones, not guaranteed publication deadlines. No trial results have been posted, and it is not established when the first efficacy analysis will become publicly available.
The trial is therefore important because of the question it is designed to answer, not because it has already demonstrated a benefit.
What a Single Hamstring Trial Can and Cannot Establish
A well-conducted randomized trial can provide evidence that uncontrolled observations cannot. But the scope of any conclusion depends on what the trial actually investigates.
The Shenzhen study focuses on a specific injury: acute grade II hamstring strain in adults aged 18 to 45.
It does not directly investigate chronic knee pain, tendon rupture, ligament reconstruction, arthritis, gastrointestinal conditions or the broad range of recovery claims circulating online.
If the study demonstrates a statistically and clinically meaningful improvement in return-to-sport time or MRI-assessed recovery, it would provide evidence supporting BPC-157’s possible activity in that particular injury setting.
It would not automatically establish effectiveness for every musculoskeletal condition.
The converse also matters. If the trial fails to show a meaningful advantage over placebo, that result would challenge claims about BPC-157’s usefulness for acute hamstring recovery under the tested conditions.
It would not necessarily answer every question about every tissue, formulation or clinical setting.
The trial’s relatively short dosing period also limits what can be learned about long-term safety.
FDA reviewers previously raised concerns about the immunogenicity of certain peptides used in compounding. Immunogenicity refers to the possibility that a substance or its impurities may provoke an unwanted immune response.
Detecting uncommon or delayed adverse reactions generally requires more participants, longer observation or repeated-exposure data than a relatively small, short-term injury trial can provide.
There is also a product-quality question.
A clinical trial uses materials and procedures governed by its research protocol. The identity, purity, potency, formulation and handling of substances sold through unrelated commercial channels may be different.
Even convincing trial results would not validate every product marketed as BPC-157 or prove that independent sellers supply material equivalent to the investigational product.
That is why regulatory review examines more than whether a compound can produce a biological effect. It also evaluates manufacturing controls, safety, product consistency and the relationship between benefits and risks.
The Shenzhen trial may become a major contribution to a thin human evidence base. It should not be treated as advance confirmation of a result that has not yet been reported.
A successful hamstring trial would establish evidence for a defined injury and treatment protocol. It would not turn every claim about BPC-157 into a demonstrated clinical benefit.
Why the Compounding Decision Is Not an FDA Approval
The October HHS announcement and the Shenzhen trial operate in two different regulatory and scientific systems.
The HHS policy concerns federal enforcement discretion under Section 503A compounding provisions. The clinical trial concerns whether an investigational peptide provides measurable benefit compared with placebo.
The first is a policy decision about a narrowly defined set of manufacturing and dispensing circumstances. The second is an effort to generate evidence of clinical effectiveness and safety.
Confusing them creates the impression that a government decision about compounding has somehow settled the underlying medical questions.
It has not.
FDA-approved drugs must undergo regulatory evaluation of safety and effectiveness for their proposed uses, alongside manufacturing and labeling requirements.
Compounded drugs do not receive that same premarket review. They can fulfill legitimate patient-specific medical needs, but they do not become FDA-approved simply because a licensed pharmacy prepares them or because an enforcement discretion policy addresses certain circumstances.
The new policy also does not supersede state restrictions or confer permission for every consumer, supplier or research-chemical seller to distribute BPC-157.
The distinction is especially important in a market where products may be advertised as research substances while attracting consumers interested in recovery, pain relief or performance.
HHS has described its policy as an effort to provide a more controlled alternative to some unregulated sources. Critics, including physicians and consumer-safety advocates, have warned that allowing broader compounding before adequate clinical evidence is available could expose patients to risks that remain poorly characterized.
Those positions reflect different approaches to a regulatory problem, but neither changes the basic scientific record.
The published human studies remain small and uncontrolled. The FDA has not approved BPC-157 for clinical use. And the registered randomized hamstring trial has not yet produced public results.
There is another restriction that the October policy does not change.
BPC-157 remains on the World Anti-Doping Agency’s Prohibited List under S0, Non-Approved Substances. This category applies at all times, including in competition and outside competition.
For athletes subject to anti-doping rules, an HHS policy concerning pharmacy compounding does not alter the substance’s prohibited status.
Grey Pepper has previously examined this confusion in Patients Keep Asking Pharmacists If BPC-157 Is Legal Again.
The central lesson remains the same: federal enforcement policy, FDA drug approval, clinical effectiveness and sporting eligibility are different questions.
Regulatory access is not evidence of therapeutic benefit, and the absence of enforcement action is not a safety certification.
Why the Order of Events Matters
The BPC-157 story has developed in an unusual sequence.
Years of preclinical research and informal commercial promotion came first. A small number of uncontrolled human reports followed. A federal enforcement discretion policy then arrived while the first identified registered randomized placebo-controlled hamstring trial was still without public results.
This sequence is different from the conventional path in which rigorous clinical evidence supports a formal application for drug approval.
That does not mean every policy decision must wait for a completed Phase 3 program. Compounding regulation addresses circumstances different from ordinary drug development, including individualized medical needs and the regulation of licensed pharmacies.
But it does mean that the policy should be judged on its stated legal terms rather than interpreted as a verdict on BPC-157’s therapeutic value.
The strongest current assessment of the published human evidence comes from the October 2026 systematic review, which identified 30 participants across three studies and rated the overall certainty as very low.
The next important clinical milestone is the registered Shenzhen trial, NCT07437547.
Its estimated primary completion is February 14, 2027, with overall study completion estimated for February 17, 2028. Those dates should be monitored for updates, but neither guarantees when results will be released.
If the investigators complete the trial as planned, the combination of return-to-sport assessment, MRI measurements and placebo comparison could provide a more rigorous test of BPC-157’s potential role in acute muscle injury.
Before that happens, however, claims about BPC-157’s effectiveness in humans remain inadequately established.
The trial’s design offers a way to investigate those claims. Its registration is not a positive result.
There is also a regulatory milestone ahead. HHS and FDA must eventually determine whether these peptides should be included on the formal 503A Bulks List through rulemaking, and under what conditions.
The interim enforcement approach may change if new safety information, quality concerns or regulatory decisions emerge.
For patients, clinicians and researchers, the appropriate reading is therefore cautious.
BPC-157 has an extensive preclinical literature, but only a small collection of published uncontrolled human observations. It remains unapproved by the FDA. The current federal compounding policy is conditional, temporary and distinct from an authorization to market the peptide as an approved treatment.
One registered randomized Phase 2 trial aims to provide stronger evidence for a specific hamstring injury indication. Its findings are still unknown.
The order of events matters because public enthusiasm, commercial availability and government policy can all move faster than the evidence needed to establish a treatment’s benefits and risks.
Washington has changed the compounding enforcement landscape. The clinical question remains unanswered: does BPC-157 help injured people recover better than a placebo?
Editorial note: This article evaluates the scientific evidence and regulatory status of BPC-157. It does not recommend the purchase, compounding or personal use of an unapproved investigational substance.
Disclosure: Grey Pepper’s owner also has business interests in the research-peptide market. This article distinguishes regulatory policy from clinical evidence and does not endorse BPC-157 as a treatment.
Sources and Further Reading
- U.S. Department of Health and Human Services: Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances. Federal Register, October 30, 2026.
- HHS: Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, Including Appendices A and B.
- Holland & Knight: HHS Issues Interim Enforcement Discretion Policy for Compounding of Six Peptides, November 4, 2026.
- The American Journal of Managed Care: Five Things to Know About HHS’s Interim Peptide Compounding Policy, October 29, 2026.
- Poolton JT, Minett J, Kazmi A. Human Evidence for BPC-157 in Orthopaedic and Regenerative Medicine: A Systematic Review of Efficacy and Safety. Acta Orthopaedica Belgica, October 8, 2026.
- Yuan C, et al. From Regeneration to Analgesia: The Role of BPC-157 in Tissue Repair and Pain Management. International Journal of Molecular Sciences, March 22, 2026.
- Lee E, Padgett B. Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain. Alternative Therapies in Health and Medicine, 2021.
- Effect of BPC-157 on Symptoms in Patients With Interstitial Cystitis: A Pilot Study, 2024.
- Lee E, Burgess K. Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study. Alternative Therapies in Health and Medicine, 2025.
- ClinicalTrials.gov: BPC 157 for Acute Hamstring Muscle Strain Repair. NCT07437547, Phase 2 Trial Registration.
- Pharmacy Times: Heal or Harm — Body Protective Compound-157 in the Gray Zone, July 1, 2026.
- Sport Integrity Australia: BPC-157 and the World Anti-Doping Code Prohibited List.
